News Skin Analytics' dermatology AI backed for NHS use An AI-powered tool for triaging patients with suspicious skin lesions, developed by Skin Analytics, will be used by the NHS to reduce waiting times.
News J&J shows its confidence in oral IL-23 drug for psoriasis J&J wants to turn the screw in the psoriasis market with a new head-to-head trial pitting oral IL-23 drug icotrokinra against Stelara.
News AstraZeneca builds in China as Cosette buys Mayne The reporting week has ended with a flurry of M&A as Cosette Pharma and AstraZeneca agree takeover deals.
News Galderma adds new indication for blockbuster hope Nemluvio Galderma has claimed a second FDA approval for IL-31 inhibitor Nemluvio, adding atopic dermatitis to its label.
News J&J plots filings after psoriasis drug clears phase 3 test Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial.
News Journey slips on FDA approval of rosacea therapy Journey Medical has claimed FDA approval for its Emrosi therapy for rosacea, which it thinks could become a "standard of care" drug for the common skin disorder.
R&D Modelling biologics: Challenges and opportunities, with Dr D... From AAPS 2025, an interview with Dr Dhaval Shah, professor of pharmaceutical sciences at the University of Buffalo and former Pfizer researcher.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.